Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Car-T therapies and ADCs feature among recent first-in-human study entrants.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
Varegacestat’s pivotal study reads out imminently.
The pivotal Harmoni-GI3 study has started enrolling patients.
ASH and SABCS approach.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.